In the 76 years since its launch, Cancer Research has become one of the most frequently cited cancer journals in the world, and the AACR’s scientific publishing program has expanded to eight journals to cover the full spectrum of basic, translational, clinical, and epidemiological research. With the guidance of their editorial boards and the leadership from their editors-in-chief, AACR journals serve the organization’s mission by providing forums for the most innovative cancer science.

New Editorial Leadership for Clinical Cancer Research

In January 2017, the AACR appointed Keith T. Flaherty, MD, as the new editor-in-chief of Clinical Cancer Research, the journal of clinical and translational cancer research that has provided a critical bridge between the laboratory and the clinic for more than twenty years. A world-renowned physician-scientist, Flaherty pioneered the development of targeted therapies matched to the genetic characteristics of a patient’s tumor and led clinical trials to evaluate some of these therapies. He assumed the editor-in-chief position of Clinical Cancer Research after six years as a senior editor of the journal’s melanoma section, and his considerable expertise will inform his leadership of the journal in its third decade of publication.

ACKNOWLEDGING OUTSTANDING EDITORIAL SERVICE: GEORGE C. PRENDERGAST, PHD

The AACR recognizes the achievements of George C. Prendergast, PhD, whose term of service as editor-in-chief of Cancer Research ended in 2017. His dedication and leadership have benefited the AACR publishing program as well as the cancer research community:

As the most comprehensive journal in the AACR’s scientific publishing program, Cancer Research represents the entire field of cancer science, publishing articles of broad interest and high impact in basic, translational, and clinical research. However, the field has changed rapidly over the past eight years; during his term as editor-in-chief, Dr. Prendergast had the vision to recognize these changes and expand the journal’s focus to highlight them. Under his editorial leadership, Cancer Research integrated cancer science with peripheral fields such as physics and re-emerging fields like immunology—inspiring investigators to take new approaches to the cancer problem and making the journal as dynamic as the areas it covers.

Under Dr. Prendergast’s leadership, Cancer Research achieved its highest-ever Impact Factor ranking (JCR; Clarivate Analytics, 2017) and continued to be one of the most frequently cited cancer journals in the world. He achieved this ranking by attracting and publishing high-impact studies; the three most-cited articles in the journal during his tenure are listed below:

• Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
  [Rahib et al., June 2014]
• Long Noncoding RNA HOTAIR Regulates Polycomb-Dependent Chromatin Modification and Is Associated with Poor Prognosis in Colorectal Cancers
  [Kogo et al., October 2011]
• Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
  [Gutschner et al., February 2013]